Anti-SEMA4D Binding Molecule for Neurodegenerative Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders, such as Alzheimer's and Huntington's disease, lack effective methods to predict treatment response and alleviate symptoms associated with SEMA4D signaling in the central nervous system.
Innovation Solution
The use of isolated antibodies or antigen-binding fragments that specifically bind to semaphorin-4D (SEMA4D), inhibiting its binding to receptors like Plexin-B1 and Plexin-B2, administered based on standardized cognitive and functional impairment assessment scores to determine eligibility and predict treatment effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standardized cognitive and functional assessment tests are used to predict treatment response, then treatment effectiveness can be predicted, but the complexity of the diagnostic process increases
Solution Approach 1:
The patent applies preliminary action by implementing standardized cognitive and functional assessment tests (MoCA, TFC, CGIC, CGIS) before treatment to predict treatment response in advance. This allows clinicians to identify patients likely to benefit from anti-SEMA4D therapy before administering treatment, thereby improving treatment reliability while maintaining a structured diagnostic workflow.
2Reliability
If anti-SEMA4D binding molecules are administered to treat neurodegenerative disorders, then disease progression can be slowed and symptoms reduced, but the heterogeneity of neurodegenerative diseases makes it difficult to determine which patients will respond
Solution Approach 1:
The patent applies local quality by differentiating patient selection criteria based on specific disease stages and types. It identifies particular patient groups (e.g., mild cognitive impairment, mild dementia, Stage I or Stage II Huntington's disease) who are most likely to respond to anti-SEMA4D therapy, rather than applying a uniform treatment approach to all neurodegenerative disease patients.
Solution Approach 2:
The patent applies parameter changes by using standardized assessment scores (MoCA, TFC, CGIC, CGIS) as quantitative parameters to determine treatment eligibility. These measurable parameters allow for objective patient selection and prediction of treatment response, transforming the subjective assessment of treatment suitability into a quantifiable process.
3Measurement precision
If cognitive and functional assessment tests are administered to all patients, then treatment response can be predicted, but the time required for diagnosis increases
Solution Approach 1:
The patent implements preliminary action by administering standardized cognitive and functional assessment tests before treatment initiation to establish baseline measurements and predict treatment response. This preliminary assessment enables early identification of patients likely to benefit from anti-SEMA4D therapy, improving prediction accuracy while establishing a time-efficient diagnostic protocol.
Data Source
AI summary
Provided herein are methods for selecting subjects having a neurodegenerative disorder for treatment with an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D), method for predicting the treatment outcome of subjects having a neurodegenerative disorder that are treated with an isolated binding molecule which specifically binds to SEMA4D and methods for treating subjects having a neurodegenerative disorder with an isolated binding molecule which specifically binds to SEMA4D.